Literature DB >> 15297505

Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

M A Pfaller1, K C Hazen, S A Messer, L Boyken, S Tendolkar, R J Hollis, D J Diekema.   

Abstract

The accuracy of antifungal susceptibility tests is important for accurate resistance surveillance and for the clinical management of patients with serious infections. Our main objective was to compare the results of fluconazole disk diffusion testing of Candida spp. performed by ARTEMIS participating centers with disk diffusion and MIC results obtained by the central reference laboratory. A total of 2,949 isolates of Candida spp. were tested by NCCLS disk diffusion and reference broth microdilution methods in the central reference laboratory. These results were compared to the results of disk diffusion testing performed in the 54 participating centers. All tests were performed and interpreted following NCCLS recommendations. Overall categorical agreement between participant disk diffusion test results and reference laboratory MIC results was 87.4%, with 0.2% very major errors (VME) and 3.3% major errors (ME). The categorical agreement between the disk diffusion test results obtained in the reference laboratory with the MIC test results was similar: 92.8%. Likewise, good agreement was observed between participant disk diffusion test results and reference laboratory disk diffusion test results: 90.4%, 0.4% VME, and 3.4% ME. The disk diffusion test was especially reliable in detecting those isolates of Candida spp. that were characterized as resistant by reference MIC testing. External quality assurance data obtained by surveillance programs such as the ARTEMIS Global Antifungal Surveillance Program ensure the generation of useful surveillance data and result in the continued improvement of antifungal susceptibility testing practices.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297505      PMCID: PMC497595          DOI: 10.1128/JCM.42.8.3607-3612.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 2.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing.

Authors:  F C Tenover; M J Mohammed; J Stelling; T O'Brien; R Williams
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group.

Authors:  J Meis; M Petrou; J Bille; D Ellis; D Gibbs
Journal:  Diagn Microbiol Infect Dis       Date:  2000-04       Impact factor: 2.803

7.  Fluconazole disk diffusion test with methylene blue- and glucose-enriched Mueller-Hinton agar for determining susceptibility of Candida species.

Authors:  S C Lee; C P Fung; N Lee; L C See; J S Huang; C J Tsai; K S Chen; W B Shieh
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

8.  Fluconazole disk diffusion susceptibility testing of Candida species.

Authors:  W R Kirkpatrick; T M Turner; A W Fothergill; D I McCarthy; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

9.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; R J Hollis; C Rice; S Tendolkar; D J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

10.  Flucytosine resistance is restricted to a single genetic clade of Candida albicans.

Authors:  Claude Pujol; Michael A Pfaller; David R Soll
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  27 in total

1.  In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.

Authors:  Ana Carolina Azevedo; Fernando César Bizerra; Daniel Arquimedes da Matta; Leila Paula de Almeida; Robert Rosas; Arnaldo Lopes Colombo
Journal:  Mycopathologia       Date:  2010-12-23       Impact factor: 2.574

Review 2.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

5.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

7.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

8.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

9.  Disk diffusion testing using Candida sp. colonies taken directly from CHROMagar Candida medium may decrease time required to obtain results.

Authors:  Michael Klevay; Alex Ebinger; Daniel Diekema; Shawn Messer; Richard Hollis; Michael Pfaller
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

10.  Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.